⌘+K

February 1, 2026The Lancet Haematology

Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial

View at Publisher

Ask AI

Bookmark

Share

Key Points

Varnimcabtagene shows promise in treating relapsed or refractory acute lymphoblastic leukaemia in adults, achieving positive outcomes.
In a phase 2 trial, 75% of participants responded favorably by the end of treatment, indicating substantial potential.
This multicentre trial demonstrated effective immunotherapy approaches for acute lymphoblastic leukaemia management.
Findings suggest that varnimcabtagene autoleucel could become a new standard in treating relapsed cases of this leukaemia.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Phase 2 trial evaluates the efficacy of varnimcabtagene in adults with relapsed leukaemia, indicating improvement possibilities.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Ortiz-Maldonado et al. (2026) studied this question.

synapsesocial.com/papers/69a76028c6e9836116a2c9fb https://doi.org/10.1016/s2352-3026(25)00328-x

View at Publisher

Ask AI

Bookmark

Share